97 results on '"Newcorn, Jeffrey"'
Search Results
2. Nonstimulant Treatments for ADHD
3. Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to
4. Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies
5. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder
6. Childhood Predictors of Adult Functional Outcomes in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (MTA)
7. A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults
8. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine
9. Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results
10. Childhood Factors Affecting Persistence and Desistence of Attention-Deficit/Hyperactivity Disorder Symptoms in Adulthood: Results From the MTA
11. Reduced Prefrontal Efficiency for Visuospatial Working Memory in Attention-Deficit/Hyperactivity Disorder
12. Randomized, Double-Blind Trial of Guanfacine Extended Release in Children With Attention-Deficit/Hyperactivity Disorder: Morning or Evening Administration
13. Editorial: Attention-Deficit/Hyperactivity Disorder, Stimulant Medication, and Criminality: Commentary and Caution
14. Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults
15. Medication Adherence in the MTA: Saliva Methylphenidate Samples Versus Parent Report and Mediating Effect of Concomitant Behavioral Treatment
16. The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study
17. Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study
18. Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder
19. 5.13 Evaluation of the Efficacy of Viloxazine ER in ADHD Inattentive and Combined Presentations
20. 5.10 ADHD Symptom Assessment Using Artificial Intelligence to Parse Virtual Reality Task Performance
21. 41.2 Comparative Effectiveness and Pathways to Care: Opportunities and Pitfalls in Selection and Sequencing of ADHD Drug Treatments
22. Optimizing and Personalizing ADHD Treatment: What We Have Learned and Where Do We Need to Go
23. Childhood Abuse, Nonadherence, and Medical Outcome in Pediatric Liver Transplant Recipients
24. High-Dose Atomoxetine Treatment of ADHD in Youths With Limited Response to Standard Doses
25. Atomoxetine Treatment for Pediatric Patients With Attention-Deficit/Hyperactivity Disorder With Comorbid Anxiety Disorder
26. Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up
27. Delinquent Behavior and Emerging Substance Use in the MTA at 36 Months: Prevalence, Course, and Treatment Effects
28. Secondary Evaluations of MTA 36-Month Outcomes: Propensity Score and Growth Mixture Model Analyses
29. 3-Year Follow-up of the NIMH MTA Study
30. Pharmacotherapy of Aggression in a 9-Year-Old With ADHD
31. Effect of Two Different Methods of Initiating Atomoxetine on the Adverse Event Profile of Atomoxetine
32. Low birth weight and risk of affective disorders and selected medical illness in offspring at high and low risk for depression
33. Family and Cognitive Factors: Modeling Risk for Aggression in Children With ADHD
34. Do Children and Adolescents With ADHD Respond Differently to Atomoxetine?
35. Elevated Childhood Serotonergic Function Protects Against Adolescent Aggression in Disruptive Boys
36. Atomoxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
37. Atomoxetine Alone or Combined With Fluoxetine for Treating ADHD With Comorbid Depressive or Anxiety Symptoms
38. Brain Activation Gradients in Ventrolateral Prefrontal Cortex Related to Persistence of ADHD in Adolescent Boys
39. ADHD AND SUBSTANCE USE DISORDER: EMERGING CONCEPTS
40. GETTING SET UP FOR MEANINGFUL MEASUREMENT-BASED CARE: OUTCOMES, INSTRUMENT SELECTION, AND IMPLEMENTATION
41. The Services for Children and Adolescents–Parent Interview: Development and Performance Characteristics
42. Reliability, Validity, and Preliminary Normative Data for the Children's Aggression Scale–Teacher Version
43. Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label Trial
44. Emergency/Adjunct Services and Attrition Prevention for Randomized Clinical Trials in Children: The MTA Manual-Based Solution
45. Socioeconomic Status as a Moderator of ADHD Treatment Outcomes
46. Development, Reliability, and Validity of the Children's Aggression Scale-Parent Version
47. 47.1 CHALLENGES IN PRESCRIBING AND OPTIMIZING PHARMACOTHERAPY IN ADOLESCENTS WITH ADHD DURING COVID-19
48. Methylphenidate Dosage for Children With ADHD Over Time Under Controlled Conditions: Lessons From the MTA
49. Multimodal Treatment of ADHD in the MTA: An Alternative Outcome Analysis
50. Symptom Profiles in Children With ADHD: Effects of Comorbidity and Gender
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.